Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3370-3379

  Goyeneche, Alicia A ^a   Carón, Rubén W ^a,b   Telleria, Carlos M ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MIFEPRISTONE; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSTASIS; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MIFEPRISTONE; OVARIAN NEOPLASMS; PROTEIN KINASES;

EID: 34250619594     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0164     Document Type: Article

References (68)

1. Philibert D, Moguilewsky M, Mary I, et al. Pharmacological profile of RU486 in animals. In: Baulieu EE, Segal SJ, editors. The antiprogesterone steroid RU486 and human fertility control. NY: Plenum Press; 1985.
2. Ho PC, Yu Ng EH, Tang OS. Mifepristone: contraceptive and non-contraceptive uses. Curr Opin Obstet Gynecol 2002;14:325-30.
3. Nordeen SK, Bona BJ, Moyer ML. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 1993;7:731-42.
4. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 1993;268: 9262-6.
5. Kahmann S, Vassen L, Klein-Hitpass L. Synergistic enhancement of PRB-mediated RU486 and R5020 agonist activities through cyclic adenosine 3′,5′-monophosphate represents a delayed primary response. Mol Endocrinol 1998;12:278-89.
6. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A 2002;99:7940-4.
7. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9 Suppl 1:116-20.
8. Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2004;9:167-77.
9. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995;64: 187-90.
10. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103: 1331-6.
11. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994;80:527-34.
12. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74:861-6.
13. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9 Suppl 1:202-7.
14. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149-68.
15. Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 2003;23:369-80.
16. Yokoyama Y, Shinohara A, Takahashi Y, et al. Synergistic effects of danazol and mifepristone on the cytotoxicity of UCN-01 in hormone-responsive breast cancer cells. Anticancer Res 2000;20:3131-5.
17. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 2004;10:5215-25.
18. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49:2851-6.
19. Romieu G, Maudelonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987;74:455-61.
20. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70.
21. Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-7.
22. Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 1998; 5:334-8.
23. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000; 74:1014-9.
24. Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 2003;88:713-9.
25. El Etreby MF, Liang Y, Johnson MH, Lewis RW. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000;42:99-106.
26. Li DQ, Wang ZB, Bai J, et al. Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 2004; 10:2628-31.
27. Rose FV, Barnea ER. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 1996;12:999-1003.
28. Qin TN, Wang LL. Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism. Di Yi Jun Yi Da Xue Xue Bao 2002;22: 344-6.
29. Liu Y, Wang LL, Deng Y. Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo. Di Yi Jun Yi Da Xue Xue Bao 2003;23:242-4.
30. Rocereto TF, Saul HM, Aikins JA, Jr., Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-32.
31. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-94.
32. Freshney I. Application of cell cultures to toxicology. Cell Biol Toxicol 2001;17:213-30.
33. Decherchi P, Cochard P, Gauthier P. Dual staining assessment of Schwann cell viability within whole peripheral nerves using calcein-AM and ethidium homodimer. J Neurosci Methods 1997;71:205-13.
34. 2+ and plasma membrane fluidity in cultured cardiac cells. Biochim Biophys Acta 1993;1145:58-62.
35. Seville LL, Shah N, Westwell AD, Chan WC. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 2005; 5:159-70.
36. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 1997;11:54-66.
37. Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 2000;20:2581-91.
38. 1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8.
39. Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res 2004;6:R130-9.
40. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36: 131-49.
41. Sui L, Dong Y, Ohno M, et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83:56-63.
42. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;13:65-70.
43. Rosen DG, Yang G, Cai KQ, et al. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 2005;11: 632-7.
44. Attwooll C, Denchi EL, Helin K. The E2F family: specific functions and overlapping interests. Embo J 2004;23:4709-16.
45. Graniela Sire EA, Vikhanskaya F, Broggini M. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann Oncol 1995;6: 589-93.
46. Reid T, Jin X, Song H, Tang HJ, Reynolds RK, Lin J. Modulation of Janus kinase 2 by p53 in ovarian cancer cells. Biochem Biophys Res Commun 2004;321:441-7.
47. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003;63: 7081-8.
48. Casalini P, Botta L, Menard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 2001; 276:12449-53.
49. Havrilesky L, Darcy M, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3814-25.
50. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR. cis-Diammine dichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1996;37:463-71.
51. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002;62:6559-65.
52. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989;32:21-5.
53. Heikinheimo O, Lahteenmaki PL, Koivunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987;2:379-85.
54. Shoupe D, Mishell DR, Jr., Lahteenmaki P, et al. Effects of the antiprogesterone RU 486 in normal women. I. Single-dose administration in the midluteal phase. Am J Obstet Gynecol 1987;157:1415-20.
55. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, Chrousos GP. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 1987; 241:401-6.
56. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005;84:1719-26.
57. Horwitz KB. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. Endocrinology 1985;116: 2236-45.
58. Lin VC, Aw SE, Ng EH, Tan MG. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer 2001;85:1978-86.
59. Akahira J, Suzuki T, Ito K, et al. Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 2002;93: 807-15.
60. Hamilton TC, Behrens BC, Louie KG, Ozols RF. Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. J Clin Endocrinol Metab 1984;59:561-3.
61. Keith Bechtel M, Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 2001; 82:127-38.
62. McDonnel AC, Murdoch WJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol 2001; 78:185-91.
63. Mao J, Regelson W, Kalimi M. Molecular mechanism of RU 486 action: a review. Mol Cell Biochem 1992;109:1-8.
64. Xu M, Song L, Wang Z. Effects of Dexamethasone on glucocorticoid receptor expression in a human ovarian carcinoma cell line 3AO. Chin Med J Engl 2003;116:392-5.
65. Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: a new role for RU-486 and related compounds. J Clin Invest 1994;94:1990-5.
66. Roberts CP, Parthasarathy S, Gulati R, Horowitz I, Murphy AA. Effect of RU-486 and related compounds on the proliferation of cultured macrophages. Am J Reprod Immunol 1995;34:248-56.
67. Liberto M, Cobrinik D. Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Letters 2000;154: 151-61.
68. Liu M, Wikonkal NM, Brash DE. Induction of cyclin-dependent kinase inhibitors and G(1) prolongation by the chemopreventive agent N-acetylcysteine. Carcinogenesis 1999;20:1869-72.